Related Experiment Video
Updated: Jul 17, 2026

Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity
Cai Bowen1, August Stuart, Jeong-Ho Ju
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007-2197, USA.
Abstract:
The prostate-specific homeodomain protein NKX3.1 is a tumor suppressor that is commonly down-regulated in human prostate cancer. Using an NKX3.1 affinity column, we isolated topoisomerase I (Topo I) from a PC-3 prostate cancer cell extract. Topo I is a class 1B DNA-resolving enzyme that is ubiquitously expressed in higher organisms and many prokaryotes. NKX3.1 interacts with Topo I to enhance formation of the Topo I-DNA complex and to increase Topo I cleavage of DNA. The two proteins interacted in affinity pull-down experiments in the presence of either DNase or RNase. The NKX3.1 homeodomain was essential, but not sufficient, for the interaction with Topo I. NKX3.1 binding to Topo I occurred independently of the Topo I NH2-terminal domain. The binding of equimolar amounts of Topo I to NKX3.1 caused displacement of NKX3.1 from its cognate DNA recognition sequence. Topo I activity in prostates of Nkx3.1+/- and Nkx3.1-/- mice was reduced compared with wild-type mice, whereas Topo I activity in livers, where no NKX3.1 is expressed, was independent of Nkx3.1 genotype. Endogenous Topo I and NKX3.1 could be coimmunoprecipitated from LNCaP cells, where NKX3.1 and Topo I were found to colocalize in the nucleus and comigrate within the nucleus in response to either gamma-irradiation or mitomycin C exposure, two DNA-damaging agents. This is the first report that a homeodomain protein can modify the activity of Topo I and may have implications for organ-specific DNA replication, transcription, or DNA repair.
Insights
The prostate tumor suppressor NKX3.1 interacts with Topoisomerase I (Topo I), enhancing its DNA cleavage activity. This interaction, crucial for DNA repair and replication, is reduced in Nkx3.1 deficient mice prostates.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- NKX3.1 is a prostate-specific homeodomain protein and a known tumor suppressor.
- Down-regulation of NKX3.1 is common in human prostate cancer.
- Topoisomerase I (Topo I) is a vital DNA-resolving enzyme involved in DNA replication, transcription, and repair.
Purpose of the Study:
- To investigate the interaction between NKX3.1 and Topo I.
- To determine how NKX3.1 affects Topo I activity.
- To explore the functional implications of this interaction in prostate cancer.
Main Methods:
- Affinity purification using an NKX3.1 column to isolate interacting proteins.
- Co-immunoprecipitation assays to confirm protein-protein interactions.
- In vivo studies using Nkx3.1 knockout mice to assess Topo I activity.
- Cellular localization studies using microscopy.
Main Results:
- Topoisomerase I (Topo I) was identified as an NKX3.1-interacting protein.
- NKX3.1 enhances Topo I's ability to form DNA complexes and cleave DNA.
- The NKX3.1 homeodomain is essential for this interaction.
- Topo I activity is reduced in the prostates of mice lacking Nkx3.1.
- NKX3.1 and Topo I co-localize in the nucleus and their interaction is modulated by DNA-damaging agents.
Conclusions:
- NKX3.1 directly interacts with Topoisomerase I, modulating its enzymatic activity.
- This interaction enhances Topo I-mediated DNA cleavage, suggesting a role in DNA repair or replication.
- The findings reveal a novel mechanism by which a homeodomain protein regulates a key DNA enzyme, with potential implications for prostate cancer therapy.
Related Concept Videos
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Co-activators and Co-repressors
Inheritance of Chromatin Structures
RNA Polymerase II Accessory Proteins
